Glaxosmithkline Pharmaceuticals Ltd Share Price

Pharmaceuticals - Multinational

NSE: GLAXO Mid Cap ISIN: INE159A01016

As on 22 January 2025 at 14:59 IST

₹2,105.75

-40.25

(-1.88%)

Sell Buy

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) is a prominent research-based pharmaceutical and healthcare company. The company specializes in developing and marketing various prescription medicines and vaccines. It operates in the pharmaceutical sector. The company was founded on November 13, 1924, under H.J. Foster & Co. Limited. GlaxoSmithKline Pharmaceuticals Ltd headquarters is in Mumbai, Maharashtra, India. GSK India’s main products include a variety of prescription medicines and vaccines. The company’s medicines address many health conditions, while its vaccines help prevent diseases such as hepatitis A and B, pertussis, rotavirus, and cervical cancer. Read More...

Over 1 Month

-5.99%

Over 6 Months

-18.13%

Over 1 Year

-3.59%

Over 3 Years

24.15%

Glaxosmithkline Pharmaceuticals Ltd Summary

Close ₹ 2,105.75

Open ₹ 2,151.35

High ₹ 2,164.85

Low ₹ 2,089.40

Volume 2,34,721

Net Turnover (in ₹) ₹ 36,38,25,816.20

52Wk High ₹ 3,088

52Wk Low ₹ 1,842.05

52Wk High / Low

1,842.05

3,088

Glaxosmithkline Pharmaceuticals Ltd Fundamentals

Key Financial Data

Market Cap (in ₹Cr) ₹ 36,354.53

EPS (TTM) 46.98

Book Value (BV) 98.85

Div. Yield 1.49 %

P/E (TTM) 54.24

Price/Book Value 21.67

Delivery % 43.96 %

Face Value 10

Key Ratios

PE Ratio 56.31

PB Ratio 18.45

EV to Sales 9.35

PEG Ratio -14.75

ROA 28.53

ROE 36.83

Debt-Equity 0.01

Net Profit Margin 19.11

Operating Profit Margin 28.60

Glaxosmithkline Pharmaceuticals Ltd Financials

Profit and Loss

Consolidated

Standalone

Yearly

Quarterly

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	3,576.30	3,352.38	3,353.80	3,036.18	3,303.39
Total Expenses	2,616.50	2,515.02	2,586.33	2,409.60	2,656.15
Profit Before Tax	816.19	836.40	779.05	453.99	305.75
Profit After Tax	589.96	607.64	380.77	287.27	93.20
Operating Profit after Depreciation	961.60	839.18	769.47	630.12	653.58

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	320.36	328.90	329.44	385.56	756.59
Total Non Current Assets	758.20	832.32	925.25	912.01	1,360.66
Total Current Assets	2,798.42	2,494.26	3,708.03	2,202.64	1,774.88
TOTAL ASSETS	3,556.62	3,326.58	4,633.28	3,114.65	3,135.54
Total Shareholder's Fund	1,777.64	1,741.27	2,662.96	1,478.26	1,820.60

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	582.02	484.23	810.75	577.91	490.50
Net Cash used in Investing Activities	8.71	807.85	-405.51	418.03	-56.84
Net Cash used in Financing Activities	-561.50	-1,543.32	-524.24	-695.56	-427.62

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Total Revenue	3,530.73	3,317.86	3,293.72	3,030.66	3,302.24
Total Expenses	2,578.08	2,484.50	2,531.86	2,404.84	2,655.24
Profit Before Tax	809.04	832.39	773.44	453.23	322.50
Profit After Tax	584.69	604.71	376.58	286.69	110.05
Operating Profit after Depreciation	954.45	835.17	763.86	629.36	653.33

Balance Sheet

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Fixed Assets	320.36	328.90	329.44	385.56	756.59
Total Non Current Assets	781.96	860.98	951.89	925.75	1,374.74
Total Current Assets	2,765.84	2,466.72	3,670.71	2,171.33	1,756.78
TOTAL ASSETS	3,547.80	3,327.70	4,622.60	3,097.08	3,131.52
Total Shareholder's Fund	1,784.09	1,753	2,677.62	1,497.12	1,840.04

Cash Flow

Particulars (in ₹ Cr.)	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Net Cash from Operating Activities	578.94	487.94	819.79	594.87	490.97
Net Cash used in Investing Activities	14.97	805.19	-419.66	407.57	-63.10
Net Cash used in Financing Activities	-561.50	-1,544.18	-524.24	-695.56	-427.62

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,010.77	814.65	929.80	805.26	956.99
Total Expenses	689.06	584.11	672.54	587.20	667.50
Profit Before Tax	343.81	249.40	270.62	65.43	299.16
Profit After Tax	252.50	182.33	194.48	45.72	217.51
Operating Profit after Depreciation	356.25	266.18	287.09	246.17	317.70

Particulars (in ₹ Cr.)	2024-09	2024-06	2024-03	2023-12	2023-09
Total Revenue	1,000.05	811	910.87	804.98	953.38
Total Expenses	681.10	581.58	655.56	587.47	666.80
Profit Before Tax	338.70	248.49	268.71	65.11	296.51
Profit After Tax	248.69	181.65	193.08	45.49	215.54
Operating Profit after Depreciation	351.14	265.27	285.18	245.85	315.05

Glaxosmithkline Pharmaceuticals Ltd Technicals

Support and Resistance

S3 S2 S1 Pivot R1 R2 R3

S1 2,103.40

S2 2,060.80

S3 2,011.50

Pivot 2,152.70

R1 2,195.30

R2 2,244.60

R3 2,287.20

Moving Average

20 SMA 2,177.97

50 SMA 2,300.08

100 SMA 2,513.18

200 SMA 2,484.36

Glaxosmithkline Pharmaceuticals Ltd Corporate Actions

Dividend

Bonus

Splits

Rights

AGM

EGM

Glaxosmithkline Pharmaceuticals Ltd

₹12/Share

Announcement Date 07 Nov 2024

Record Date 07 Nov 2024

Div Yield 120%

AGM Date: 26 Jul 2022

Annual General Meeting The Ninety Seventh Annual General Meeting will held on Tuesday, 25th July, 2022, through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. outcome of meeting Annual Report for financial year ended 31st March 2022 (As Per BSE Announcement dated on 24.06.2022) The Ninety Seventh Annual General Meeting will held on Tuesday, 25th July, 2022, through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. Publication of AGM & Evoting Add (As Per BSE Announcement Dated on 27/06/2022) Outcome of AGM (As Per BSE Announcement dated on 26.07.2022) GlaxoSmithKline Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement Dated on 27.07.2022) GlaxoSmithKline Pharmaceuticals Ltd has informed BSE regarding the details of Voting results of AGM, under Regulation 44(3) of SEBI (LODR) Regulations, 2015. (As Per BSE Announcement dated on 10.08.2022)

AGM Date: 26 Jul 2023

AGM 26/07/2023 We wish to inform you that the Company Will hold the 98th Annual General Meeting ('AGM') on Wednesday, 26th July, 2023, through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India; The Board of Directors has recommended a final dividend of Rs 32 per share for the financial year ended 31st March, 2023 on Equity Shares of Re.10/- each, subject to the approval of shareholders at the forthcoming Annual General Meeting. Has fixed Friday, 30th June 2023, as the Record Date for determining entitlement of members to final dividend for the financial year ended 31st March,2023. If the final dividend as recommended by the Board of Directors is approved at the AGM, payment of such dividend, subject to deduction of tax at source, will be made on and after Wednesday, 26th July 2023 as under: a) To all Beneficial Owners in respect of shares held in dematerialized form as per the data as may be made available by the National Securities Depository Limited and the Central Depository Services (India) Limited as of the close of business hours on Friday, 30th June 2023. b) To all Members in respect of shares held in physical form after giving effect to valid transmission or transposition requests lodged with the Company as of the close of business hours on Friday, 30th June 2023. The above information is also available on the website of the Company. Kindly take the same on your record. Ninety-Eighth Annual General Meeting of the Company (As Per BSE Announcement dated on 21.06.2023) Advertisement relating e-voting for AGM (As per BSE Announcement Dated on 22/06/2023) Proceeding of 98th AGM (As Per BSE Announcement Dated on 26.07.2023) Revised outcome of AGM - Change in page no 10 where no of shareholders present in meeting adherently was not applicable now corrected to extact no shareholders attended the meeting Revised - Change in page no 10 where inadvertently no of shareholders present was not applicable to exact no of shareholders attended the meeting (As Per BSE Announcement Dated on 02.08.2023)

AGM Date: 28 Jun 2024

The Board of Directors has fixed Frida1y, June 28, 2024 as the date of the 99th Annual General Meeting ('AGM') of the Company through Video Conferencing / Other Audio Visual Means in accordance with the relevant circulars issued by Ministry of Corporate Affairs and Securities and Exchange Board of India. 99th Annual General Meeting to be held on 28th June 2024 (As Per BSE Announcement dated on 04.06.2024) Outcome of AGM (As Per BSE Announcement dated on 28.06.2024)

Glaxosmithkline Pharmaceuticals Ltd Peer Comparison

Company	Price	Market Cap (in ₹ Cr)
Glaxosmithkline Pharmaceuticals Ltd	₹2,142.10	₹36,288.47
Sun Pharmaceuticals Industries Ltd	₹1,761.80	₹4,22,714.84
Divis Laboratories Ltd	₹5,818.40	₹1,54,460.24
Cipla Ltd	₹1,427.30	₹1,15,270.75
Dr Reddys Laboratories Ltd	₹1,288.45	₹1,07,511.36
Torrent Pharmaceuticals Ltd	₹3,157.60	₹1,06,862.73

Glaxosmithkline Pharmaceuticals Ltd News

GlaxoSmithKline Pharmaceuticals revises board meeting date

To 14 February 2025

21 Jan 2025, 11:16 am

GlaxoSmithKline Pharmaceuticals declare Quarterly Result

On 10 February 2025

15 Jan 2025, 03:27 pm

GSK Pharma gains as Q2 PAT rises 15% YoY to Rs 249 cr

Glaxosmithkline Pharmaceuticals' advanced 1.45% to Rs 2667.95 after the company's standalone net profit jumped 15.38% to Rs 248.69 crore on 4.9% increase in revenue from operations to Rs 1,000.05 crore in Q2 FY25 over Q2 FY24.

30 Oct 2024, 10:39 am

Board of GlaxoSmithKline Pharmaceuticals recommends Special Interim Dividend

Of Rs.12 per share

29 Oct 2024, 04:10 pm

GlaxoSmithKline Pharmaceuticals to declare Quarterly Result

On 29 October 2024

25 Oct 2024, 10:38 am

Glaxosmithkline Pharmaceuticals Ltd Stock Analysis

Annual revenue for Glaxosmithkline Pharmaceuticals Ltd increased by 6.42% to ₹3,530.73 crore in FY 2024 from ₹3,317.86 crore in FY 2023.
Annual Net Profit for Glaxosmithkline Pharmaceuticals Ltd decreased by 3.31% to ₹584.69 crore in FY 2024 from ₹604.71 crore in FY 2023.
Promoter Shareholding in Glaxosmithkline Pharmaceuticals Ltd remains unchanged by 0.00% in the most recent quarter, from 75% in September 2024 to 75% in December 2024.
Glaxosmithkline Pharmaceuticals Ltd delivered a 1-year return of -3.59% compared to the Nifty 50, which provided a return of 8.41% as of the last trading session.
Glaxosmithkline Pharmaceuticals Ltd share price moved down by 1.88% from its previous close of INR ₹2,146. The latest Glaxosmithkline Pharmaceuticals Ltd share price is INR ₹2,105.75.
Glaxosmithkline Pharmaceuticals Ltd share price today has been at a low of 2,089.40 and a high of 2,164.85. Over the past 52 weeks, the Glaxosmithkline Pharmaceuticals Ltd share price has seen a low of 1,842.05 and a high of 3,088.

About Glaxosmithkline Pharmaceuticals Ltd

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) is a prominent research-based pharmaceutical and healthcare company. The company specializes in developing, manufacturing, and marketing various prescription medicines and vaccines. GSK India’s product portfolio covers various therapeutic areas. These include anti-infectives and respiratory diseases.

Operating in the pharmaceutical sector, GSK India has established itself as a significant player in the industry. The company was founded on November 13, 1924, under H.J. Foster & Co. Limited. With a century of experience, GSK India has grown substantially. It has expanded its product offerings and market reach both domestically and internationally.

GlaxoSmithKline Pharmaceuticals Ltd's headquarters is in Mumbai, Maharashtra, India. The company's promoters include Glaxo Group Limited, with a 35.99% stake. A team of professional managerial promoters manages the operations of the company that includes-

R S Karnad
B Akshikar
J Chandy
S Williams
M Anand

GSK India’s main products include a variety of prescription medicines and vaccines. The company’s medicines address many health conditions. Its vaccines help prevent several diseases, including hepatitis A and B, influenza, and chickenpox. They also protect against diphtheria, pertussis, tetanus, rotavirus, and cervical cancer. These products are essential for improving public health. They also play a critical role in preventing the spread of infectious diseases.

While GSK India is a significant player in the pharmaceutical sector, it is not the largest in terms of market share. It also does not hold the top position in market capitalization. However, it holds a strong position in specific therapeutic areas. This is particularly true in the development and distribution of vaccines. This leadership is a testament to the company’s expertise and commitment to quality and innovation. The registered office of GlaxoSmithKline Pharmaceuticals Ltd is in Mumbai, Maharashtra. The registrar's office is located in Hyderabad, Telangana.

The vision of GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Ltd (GSK India) has a clear and inspiring vision. This vision guides its operations and strategic initiatives. The company’s vision is to improve the quality of human life by enabling people to do more, feel better, and live longer. GSK India aims to be a leader in the pharmaceutical and healthcare sectors. It focuses on providing innovative and high-quality products. These products are designed to address the evolving needs of patients and healthcare providers.

The vision of GSK India emphasizes the importance of scientific innovation. The company invests heavily in research and development to create cutting-edge medicines and vaccines that tackle some of the world’s most challenging health issues. This focus on innovation ensures that GSK remains at the forefront of medical advancements, offering products that improve patient outcomes and enhance the quality of life. The company’s R&D efforts are directed toward developing new treatments for diseases such as cancer, respiratory conditions, and infectious diseases.

Quality is another cornerstone of GSK India’s vision. The company strives to maintain the highest standards in all its operations. This commitment extends from product development to manufacturing and distribution. GSK's commitment to quality is reflected in its rigorous quality control processes. It also adheres to international standards. This dedication to quality has earned the company a strong reputation. It is well-regarded by both healthcare professionals and patients. It has also helped the company build long-term relationships with its stakeholders.

Sustainability is a critical component of GSK India’s vision. The company recognizes the importance of environmental responsibility. It is committed to reducing its environmental footprint. GSK focuses on developing eco-friendly products and implementing sustainable manufacturing practices. The company aims to minimize waste and reduce energy consumption. It also focuses on using environmentally friendly materials.

GSK India’s vision also includes a strong focus on patient-centricity. The company aims to exceed patient expectations. It does this by providing high-quality products and exceptional service. GSK works closely with healthcare providers to understand the needs of patients. This collaboration helps them develop customized solutions that meet specific requirements. This patient-centric approach has helped the company build a loyal customer base and grow sustainably.

The company’s vision extends to its employees as well. GSK India believes its employees are its greatest asset and is committed to creating a positive and inclusive work environment. The company invests in employee development and provides continuous learning and growth opportunities. GSK’s vision includes fostering a culture of innovation, collaboration, and excellence, where employees feel valued and motivated to contribute to the company’s success.

GSK India’s vision also encompasses its role in the community. The company is committed to positively impacting society through its corporate social responsibility initiatives. GSK engages in various activities to improve community health, education, and well-being. The company’s vision includes supporting local communities and contributing to their development through sustainable and impactful initiatives.

The vision of GSK India is also reflected in its global expansion strategy. The company aims to strengthen its presence in existing markets and explore new opportunities in emerging markets. GSK’s global expansion is driven by a deep understanding of local markets and a commitment to delivering high-quality products that meet customers' specific needs in different regions. This global perspective is critical to the company’s vision and is essential for its long-term growth and success.